1. Home
  2. NVRI vs PCRX Comparison

NVRI vs PCRX Comparison

Compare NVRI & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Enviri Corporation

NVRI

Enviri Corporation

HOLD

Current Price

$17.80

Market Cap

996.0M

Sector

Miscellaneous

ML Signal

HOLD

Logo Pacira BioSciences Inc.

PCRX

Pacira BioSciences Inc.

HOLD

Current Price

$26.63

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NVRI
PCRX
Founded
1853
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Diversified Commercial Services
Biotechnology: Pharmaceutical Preparations
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
996.0M
1.0B
IPO Year
N/A
2011

Fundamental Metrics

Financial Performance
Metric
NVRI
PCRX
Price
$17.80
$26.63
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$32.86
AVG Volume (30 Days)
2.3M
723.2K
Earning Date
11-10-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.47
Revenue
$2,244,061,000.00
$716,791,000.00
Revenue This Year
N/A
$6.24
Revenue Next Year
$3.42
$9.53
P/E Ratio
N/A
$55.78
Revenue Growth
N/A
3.14
52 Week Low
$4.72
$18.17
52 Week High
$18.74
$27.64

Technical Indicators

Market Signals
Indicator
NVRI
PCRX
Relative Strength Index (RSI) 71.78 73.86
Support Level $17.97 $25.17
Resistance Level $18.29 $24.81
Average True Range (ATR) 0.28 0.94
MACD -0.15 0.28
Stochastic Oscillator 0.56 89.16

Price Performance

Historical Comparison
NVRI
PCRX

About NVRI Enviri Corporation

Enviri Corp is a market-leading, provider of environmental solutions for industrial and specialty waste streams, and equipment and technology for the rail sector. The company's current operations consist of three divisions: Harsco Environmental, Harsco Rail, and Clean Earth. The company gains its revenue from Harsco Environmental segment. Geographically company operates in USA and International Countries, with majority revenue from USA.

About PCRX Pacira BioSciences Inc.

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

Share on Social Networks: